STAT PlusPharmalot Up and down the ladder: The latest comings and goings Manage alerts for this article Email this article Share this article By Ed SilvermanApril 24, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that Tenpoint Therapeutics hired Stephen Lane as chief medical officer. He is also executive chair at the Holland Foundation for Sight Restoration. Previously he worked at Alcon, where he was chief medical officer and head of medical safety.Advertisement But all work and no play can make for a dull chief medical officer. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, jobs, Pharmaceuticals, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot April 24, 2026 STAT Plus: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more Pharmalot April 23, 2026 STAT Plus: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards Advertisement Pharmalot April 23, 2026 STAT Plus: Pharmalittle: We’re reading about cheap telehealth visits, pharma withholding meds in Europe, and more Pharmalot April 22, 2026 STAT Plus: Pharmalittle: We’re reading about Medicare’s obesity drug pilot, an experimental Roche MS drug, and more Pharmalot April 21, 2026 STAT Plus: Pharmalittle: We’re reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more Subscriber Picks
stat· 2mo ago
saveSTAT+: Up and down the ladder: The latest comings and goings
April 24, 2026read original ↗
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
481 words · extracted 2mo agoread original ↗
🔗 mentioned in this article
related news
- Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugsstat · 2mo ago · 2 shared entities
- Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelicsbiopharma dive · 2mo ago · 2 shared entities
- STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and morestat · 2mo ago · 2 shared entities
- A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scriptsstat · 2mo ago · 2 shared entities
- STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boardsstat · 2mo ago · 2 shared entities
comments(0)
5-min edit window · permanent after that